[No standalone website (unbranded, no questionnaire)] A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site

Study’s contact

Call center

+39 340 0638165

Email address

barbara.saccon@iqvia.com

Condition

Parkinson's Disease

Treatment type

Observational

Sponsor

Zambon SpA

ClinicalTrials.gov identifier

NCT03994328

Study number

Z7219N04

Understanding clinical trials

Get answers to your questions about clinical trials.

About the study

The purpose of this study is to evaluate how safinamide, rasagiline and other SoC drugs are associated with the quality of life of PD patients by means of the Parkinson's Disease Questionnaire (PDQ)-39 items.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria
  1. Patients of both genders ≥ 18 years of age, with a clinical diagnosis of idiopathic PD according to UK Brain Bank diagnostic criteria (12) for whom safinamide, rasagiline or any other anti-Parkinson drugs are prescribed according to the current Summary of Product Characteristics (SmPC).
  2. Willing to participate in the study and able to understand and sign the written informed consent form.
  3. Patients on a stable anti-Parkinson therapy, always including L-dopa + dopa-decarboxylase inhibitor (DDI), with or without other anti-Parkinson medications.
  4. Patients must be treated with safinamide, rasagiline or other SoC drugs as add-on to L-dopa for no more than 2 months prior to the baseline visit, according to the clinical practice.
Exclusion criteria
  1. Patients with any form of Parkinsonism other than idiopathic PD.
  2. Patients for whom safinamide, rasagiline or any other anti-Parkinson drug are contraindicated according to the current SmPC.
  3. Patients known to be pregnant.
  4. Patients treated with safinamide or rasagiline who receive other concomitant MAO-B inhibitors.
  5. Patients treated with other SoC drugs who receive safinamide or rasagiline.
  6. Previous participation in a clinical trial with an investigational drug or medical device in the 3 months prior to the baseline visit.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.

Find a Study Site